NCT04465877View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

February 17, 2021

Study Completion Date

February 17, 2021

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

JTT-662

Active drug tablets containing JTT-662

DRUG

Placebo

Placebo tablets matching in appearance to the active drug tablets

Trial Locations (1)

33143

Qps-Mra, Llc, Miami

Sponsors

Lead Sponsor

Akros Pharma Inc.

All Listed Sponsors

lead

Akros Pharma Inc.

INDUSTRY

NCT04465877 - Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter